Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million, top end of prior guidance range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
- BioCryst presents evidence on high adherence, persistence rates with ORLADEYO
- BioCryst to present real-world evidence on oral ORLADEYO
- Two Key Products Drive BioCryst (BCRX) to New Highs
- BioCryst reports inducement grants under Nasdaq listing rule